Semaglutide for PCOS

What the evidence says

Evidence tier: Off-label · emerging. Off-label clinical use with emerging evidence; not FDA-approved for this indication specifically.

• Off-label use; widely prescribed for PCOS-associated metabolic dysfunction.
• Smaller weight-loss effect vs Tirzepatide but more years of safety data.
• Emerging evidence for cycle regularity and ovulation improvement.

Protocol notes

Standard weight-loss titration. Coordinate with reproductive endocrinology if pregnancy planning.

Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.

What to skip

• Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
• Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
• Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.

Where to go next

• Full Semaglutide directory entry - status, sourcing, studies, what to skip
• What are peptides - if you skipped the foundation
• How peptides actually work - mechanism in plain English
• The Tier List - which ones to take seriously
• Subscribe to the dispatch

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.

-> Subscribe free